Research programme: bradykinin B1 receptor antagonists - Amgen

Drug Profile

Research programme: bradykinin B1 receptor antagonists - Amgen

Latest Information Update: 01 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Amides; Naphthalenes; Piperazines; Pyrazines; Small molecules; Sulfonamides; Sulfones
  • Mechanism of Action Bradykinin B1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Inflammation; Pain

Most Recent Events

  • 01 Sep 2011 Preclinical development is ongoing in USA
  • 20 Aug 2009 Pharmacokinetics data from preclinical studies presented at the 238th National Meeting of the American Chemical Society (238th-ACS-2009)
  • 08 Sep 2008 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top